AstraZeneca is in discussions to acquire Bristol Myers Squibb in a potential merger valued at approximately $400 billion, which would create one of the largest pharmaceutical companies globally.

Context

This merger, if successful, would position the combined entity as the fourth-largest drugmaker in the world, significantly impacting the pharmaceutical landscape.S1

Key points

• AstraZeneca is the second-largest listed company in the UK.S1

• The merger talks could lead to a nearly $400 billion pharmaceutical group.S1

• Bristol Myers Squibb is a major US rival to AstraZeneca.S1

• AstraZeneca's market value was nearly £196 billion before the merger news.S1

• The potential deal represents one of the largest-ever mergers in the pharmaceutical sector.S1

• AstraZeneca's shares dropped by 7% following the merger report.S2

• The merger could reshape competition in the pharmaceutical industry.S1

• Pascal Soriot is the chief executive of AstraZeneca.S1

Why it matters

• The merger could enhance research and development capabilities for both companies.S1

• It may lead to significant cost savings and operational efficiencies.S1

• The deal could influence drug pricing and availability in the market.S1

What to watch

• Monitor AstraZeneca's stock performance following the merger discussions.S2

• Watch for regulatory responses to the proposed merger.S1

• Keep an eye on reactions from the pharmaceutical industry and investors.S1